7th Apr 2026 07:00
Haleon plc: Aggregated information - transactions in own shares
7 April 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 5,266,782 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.
London Stock Exchange | CBOE (UK)/BXE | CBOE (UK)/CXE | Aquis | |
Date of purchase: | 30 March 2026 | |||
Number of Shares purchased: | 400,900 | 16,735 | 20,439 | - |
Highest price paid per Share (p): | 374.7000 | 374.7000 | 374.7000 | - |
Lowest price paid per Share (p): | 368.1000 | 370.6000 | 370.6000 | - |
Volume weighted average price paid per Share (p): | 369.7187 | 372.9532 | 372.5379 | - |
Date of purchase: | 31 March 2026 | |||
Number of Shares purchased: | 559,566 | 309,537 | 430,897 | - |
Highest price paid per Share (p): | 379.1000 | 379.1000 | 379.1000 | - |
Lowest price paid per Share (p): | 373.6000 | 373.6000 | 373.6000 | - |
Volume weighted average price paid per Share (p): | 375.8642 | 376.0574 | 375.9833 | - |
Date of purchase: | 1 April 2026 | |||
Number of Shares purchased: | 794,952 | 486,092 | 718,956 | - |
Highest price paid per Share (p): | 376.3000 | 376.3000 | 376.3000 | - |
Lowest price paid per Share (p): | 370.4000 | 370.4000 | 370.4000 | - |
Volume weighted average price paid per Share (p): | 372.9529 | 373.1379 | 373.1820 | - |
Date of purchase: | 2 April 2026 | |||
Number of Shares purchased: | 613,820 | 384,073 | 530,815 | - |
Highest price paid per Share (p): | 374.1000 | 373.9000 | 374.0000 | - |
Lowest price paid per Share (p): | 369.5000 | 369.5000 | 369.5000 | - |
Volume weighted average price paid per Share (p): | 371.6621 | 371.5836 | 371.6343 | - |
Following the settlement of the above, the Company's registered share capital is 8,927,564,553 ordinary shares of £0.01 each, of which 12,493,360 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,915,071,193 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/3357Z_1-2026-4-2.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
Enquiries
|
| ||
Investors | Media
| ||
Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
Rakesh Patel | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
Email: [email protected] | Email: [email protected] | ||
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
Related Shares:
Haleon